Literature DB >> 29545008

The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women.

Anita H Clayton1, Irwin Goldstein2, Noel N Kim3, Stanley E Althof4, Stephanie S Faubion5, Brooke M Faught6, Sharon J Parish7, James A Simon8, Linda Vignozzi9, Kristin Christiansen10, Susan R Davis11, Murray A Freedman12, Sheryl A Kingsberg13, Paraskevi-Sofia Kirana14, Lisa Larkin15, Marita McCabe16, Richard Sadovsky17.   

Abstract

The International Society for the Study of Women's Sexual Health process of care (POC) for management of hypoactive sexual desire disorder (HSDD) algorithm was developed to provide evidence-based guidelines for diagnosis and treatment of HSDD in women by health care professionals. Affecting 10% of adult females, HSDD is associated with negative emotional and psychological states and medical conditions including depression. The algorithm was developed using a modified Delphi method to reach consensus among the 17 international panelists representing multiple disciplines. The POC starts with the health care professional asking about sexual concerns, focusing on issues related to low sexual desire/interest. Diagnosis includes distinguishing between generalized acquired HSDD and other forms of low sexual interest. Biopsychosocial assessment of potentially modifiable factors facilitates initiation of treatment with education, modification of potentially modifiable factors, and, if needed, additional therapeutic intervention: sex therapy, central nervous system agents, and hormonal therapy, guided in part by menopausal status. Sex therapy includes behavior therapy, cognitive behavior therapy, and mindfulness. The only central nervous system agent currently approved by the US Food and Drug Administration (FDA) for HSDD is flibanserin in premenopausal women; use of flibanserin in postmenopausal women with HSDD is supported by data but is not FDA approved. Hormonal therapy includes off-label use of testosterone in postmenopausal women with HSDD, which is supported by data but not FDA approved. The POC incorporates monitoring the progress of therapy. In conclusion, the International Society for the Study of Women's Sexual Health POC for the management of women with HSDD provides a rational, evidence-based guideline for health care professionals to manage patients with appropriate assessments and individualized treatments.
Copyright © 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29545008     DOI: 10.1016/j.mayocp.2017.11.002

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  18 in total

Review 1.  Bremelanotide: First Approval.

Authors:  Sohita Dhillon; Susan J Keam
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

2.  Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO.

Authors:  L Vignozzi; N Malavolta; P Villa; G Mangili; S Migliaccio; S Lello
Journal:  J Endocrinol Invest       Date:  2018-11-19       Impact factor: 4.256

3.  Antidepressant Use During Development May Impair Women's Sexual Desire in Adulthood.

Authors:  Tierney K Lorenz
Journal:  J Sex Med       Date:  2020-01-11       Impact factor: 3.802

Review 4.  Management of hypoactive sexual desire disorder in transgender women: a guide for clinicians.

Authors:  Carlotta Cocchetti; Jiska Ristori; Francesca Mazzoli; Linda Vignozzi; Mario Maggi; Alessandra Daphne Fisher
Journal:  Int J Impot Res       Date:  2021-02-08       Impact factor: 2.896

Review 5.  Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.

Authors:  Jessica A Pettigrew; Andrew M Novick
Journal:  J Midwifery Womens Health       Date:  2021-09-12       Impact factor: 2.388

6.  Treatment of Hypoactive Sexual Desire Disorder Among Women: General Considerations and Pharmacological Options.

Authors:  Gabriela S Pachano Pesantez; Anita H Clayton
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

7.  Perspectives in Psychopharmacology.

Authors: 
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

Review 8.  The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review.

Authors:  Maria Uloko; Farah Rahman; Leah Ibrahim Puri; Rachel S Rubin
Journal:  Int J Impot Res       Date:  2022-10-05       Impact factor: 2.408

9.  Mind-body-spirit model for the medical management of female sexual well-being.

Authors:  Tierney Lorenz; Nicola Finley
Journal:  Curr Sex Health Rep       Date:  2020-10-31

Review 10.  Pharmacotherapy for Sexual Dysfunction in Women.

Authors:  Jeong Hoo Lee; Jenny E Lee; Veronica Harsh; Anita H Clayton
Journal:  Curr Psychiatry Rep       Date:  2022-02-01       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.